World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
28557
World Ranking
13621
National Ranking
520

Henk-Jan Guchelaar publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Henk-Jan Guchelaar sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 510 publications — 60th percentile

60% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Henk-Jan Guchelaar D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Henk-Jan Guchelaar sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 87 D-Index — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2020 - Member of Academia Europaea

Overview

Henk-Jan Guchelaar is affiliated with Leiden University Medical Center in the Netherlands. Their research primarily spans the field of Medicine, with a particular focus on Pharmacology, Oncology, Pediatrics, Perinatology and Child Health, Molecular Biology, and Pulmonary and Respiratory Medicine. These specialized domains reflect the scientist's diverse expertise in biomedical sciences and clinical research.

Their scholarly output emphasizes several main topics, including Pharmacogenetics and Drug Metabolism, Pharmaceutical Studies and Practices, Colorectal Cancer Treatments and Studies, Neutropenia and Cancer Infections, Cancer Treatment and Pharmacology, Statistical Methods in Clinical Trials, and Inflammatory Mediators and NSAID Effects. This range of research topics illustrates a concentration on pharmacological interventions and cancer-related studies alongside methodologies for clinical trial analysis.

Henk-Jan Guchelaar has contributed to numerous scientific articles published across a variety of journals. Frequent publication venues include Clinical Pharmacology & Therapeutics, European Journal of Human Genetics, Frontiers in Pharmacology, British Journal of Clinical Pharmacology, and Annals of Oncology. These journals are notable for disseminating research in clinical pharmacology, genetics, oncology, and broader pharmacological sciences.

Their recent papers demonstrate active involvement in pharmacogenetics and clinical implementation studies. Selected recent publications are:

  • A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study (2023, The Lancet)
  • Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review (2020, Journal of Clinical Medicine)
  • Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics (2023, European Journal of Human Genetics)
  • Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs (2021, European Journal of Human Genetics)
  • Individualized Dosing of Fluoropyrimidine-Based Chemotherapy to Prevent Severe Fluoropyrimidine-Related Toxicity: What Are the Options? (2020, Clinical Pharmacology & Therapeutics)

Collaboration appears integral to their research, with frequent co-authors including Jesse J. Swen, Hans Gelderblom, Ron H.J. Mathijssen, Ron H. N. van Schaik, and Dirk Jan A. R. Moes. These collaborators have each contributed significantly to shared scientific output, suggesting sustained and productive research partnerships.

Recognition of Henk-Jan Guchelaar's contributions includes the award of Membership in Academia Europaea in 2020, underscoring a level of acknowledgement within the broader European scientific community.

Best Publications

  • Genetics of rheumatoid arthritis contributes to biology and drug discovery

    Yukinori Okada;Yukinori Okada;Di Wu;Di Wu;Di Wu;Gosia Trynka;Gosia Trynka;Towfique Raj;Towfique Raj

  • Pharmacogenetics: from bench to byte--an update of guidelines.

    J.J. Swen;M. Nijenhuis;A. De Boer;L. Grandia

  • Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions.

    A. Vermes;H.-J. Guchelaar;J. Dankert

  • The Risk of Cancer in Users of Statins

    Matthijs R. Graaf;Annette B. Beiderbeck;Antoine C.G. Egberts;Dick J. Richel

  • Cardiotoxicity of cytotoxic drugs.

    Kirsten J.M Schimmel;Dick J Richel;Renée B.A van den Brink;Henk-Jan Guchelaar

  • Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group.

    Kelly E. Caudle;Katrin Sangkuhl;Michelle Whirl‐Carrillo;Jesse J. Swen

  • Clinical pharmacokinetics of tyrosine kinase inhibitors.

    Nielka P. van Erp;Hans Gelderblom;Henk-Jan Guchelaar

  • Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis

    J. A. M. Wessels;T. W. J. Huizinga;H.-J. Guchelaar

  • Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer

    Matthijs R. Graaf;Dick J. Richel;Cornelis J.F. van Noorden;Henk-Jan Guchelaar

  • DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.

    Linda M. Henricks;Carin A.T.C. Lunenburg;Femke M. de Man;Didier Meulendijks

  • Liposomal drug formulations in cancer therapy: 15 years along the road.

    Marije Slingerland;Henk-Jan Guchelaar;Hans Gelderblom

  • Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium

    C. H. van der Wouden;A. Cambon-Thomsen;E. Cecchin;K. C. Cheung

  • Making sense of big data in health research: Towards an EU action plan

    Charles Auffray;Charles Auffray;Rudi Balling;Inês Barroso;László Bencze

  • A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis.

    Judith A. M. Wessels;Sjoerd M. van der Kooij;Saskia le Cessie;Wietske Kievit

  • Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single‐nucleotide polymorphisms in genes coding for folate pathway enzymes

    Judith A. M. Wessels;Jeska K. de Vries-Bouwstra;Bas T. Heijmans;P. Eline Slagboom

  • Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.

    Matthew P. Goetz;Katrin Sangkuhl;Henk Jan Guchelaar;Matthias Schwab

  • Pharmacogenetics: From Bench to Byte

    J.J. Swen;I. Wilting;AL De Goede;L. Grandia

  • Translating pharmacogenomics : Challenges on the road to the clinic

    Jesse J. Swen;Tom W J Huizinga;Hans Gelderblom;Elisabeth G E de Vries

  • Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity

    Nielka P. van Erp;Karel Eechoute;Astrid A. van der Veldt;John B. Haanen

  • Radiation-induced Xerostomia: Pathophysiology, Clinical Course and Supportive Treatment

    Guchelaar Hj;Vermes A;Meerwaldt Jh

Frequent Co-Authors

Hans Gelderblom
Hans Gelderblom Leiden University Medical Center
Jan H.M. Schellens
Jan H.M. Schellens Utrecht University
Tom W. J. Huizinga
Tom W. J. Huizinga Leiden University Medical Center
Ron H.J. Mathijssen
Ron H.J. Mathijssen Erasmus University Rotterdam
Hein Putter
Hein Putter Leiden University Medical Center
Cornelis J. A. Punt
Cornelis J. A. Punt University of Amsterdam
Jos H. Beijnen
Jos H. Beijnen Utrecht University
J.H. Frederik Falkenburg
J.H. Frederik Falkenburg Leiden University Medical Center
Ron H.N. van Schaik
Ron H.N. van Schaik Erasmus University Rotterdam
Cristina Rodríguez-Antona
Cristina Rodríguez-Antona Alberto Sols Biomedical Research Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in medicine doesn't always mean becoming a doctor. There are many alternative healthcare degrees online that offer rewarding career paths and greater flexibility. From clinical roles to administrative specialties, students can find affordable programs that fit various interests and budgets.

For those interested in healthcare administration, exploring the medical billing and coding cost can help you understand the investment required to start in this growing field. If you're aiming for advanced clinical practice, there are cheapest np programs online that allow nurses to qualify as nurse practitioners at a lower cost.

Entry-level nursing remains highly accessible as well, with plenty of affordable nursing programs online for both aspiring and current nurses. For those looking to advance into leadership or academic positions, you can explore the cheapest dnp programs online which offer a route to a doctoral degree in nursing without a huge financial burden.

Whether you’re just starting or seeking to advance your healthcare career, these online degree options open doors to new opportunities and provide cost-effective alternatives to traditional medical school.

Best Scientists Citing Henk-Jan Guchelaar

Trending Scientists

Recently Published Articles